

Recurrent *de novo* missense variants across multiple histone H4 genes underlie a neurodevelopmental syndrome

Authors

Federico Tessadori, Karen Duran,
Karen Knapp, ..., Peter D. Mace, Louise S. Bicknell,
Gijs van Haften

Correspondence

louise.bicknell@otago.ac.nz (L.S.B.),
g.vanhaaften@umcutrecht.nl (G.v.H.)



Tessadori et al., 2022, The American Journal of Human Genetics 109, 750–758

April 7, 2022 © 2022 The Author(s).

<https://doi.org/10.1016/j.ajhg.2022.02.003>

(Affiliations continued on next page) The CellPress logo, featuring a stylized 'e' and the word "CellPress".

Recurrent *de novo* missense variants across multiple histone H4 genes underlie a neurodevelopmental syndrome

Federico Tessadori,¹ Karen Duran,² Karen Knapp,³ Matthias Fellner,³ Deciphering Developmental Disorders Study, Sarah Smithson,⁴ Ana Beleza Meireles,⁴ Mariet W. Elting,⁵ Quinten Waisfisz,⁵ Anne O'Donnell-Luria,^{6,7,8} Catherine Nowak,⁸ Jessica Douglas,⁸ Anne Ronan,⁹ Theresa Brunet,^{10,11} Urania Kotzaeridou,¹² Shayna Svihovec,¹³ Margarita S. Saenz,¹³ Isabelle Thiffault,^{14,15,16} Florencia Del Viso,^{15,16} Patrick Devine,¹⁷ Shannon Rego,¹⁷ Jessica Tenney,¹⁸ Arie van Haeringen,¹⁹ Claudia A.L. Ruivenkamp,¹⁹ Saskia Koene,¹⁹ Stephen P. Robertson,²⁰ Charulata Deshpande,²¹ Rolph Pfundt,²² Nienke Verbeek,²³ Jiddeke M. van de Kamp,⁷ Janneke M.M. Weiss,^{7,22} Anna Ruiz,²⁴ Elisabeth Gabau,²⁵ Ehud Banne,²⁶ Alexander Pepler,²⁷ Armand Bottani,²⁸ Sacha Laurent,²⁹ Michel Guipponi,²⁹ Emilia Bijlsma,¹⁹ Ange-Line Bruel,^{30,31} Arthur Sorlin,³² Mary Willis,³³ Zoe Powis,³⁴ Thomas Smol,³⁵ Catherine Vincent-Delorme,³⁶ Diana Baralle,³⁷ Estelle Colin,³⁸ Nicole Revencu,³⁹

(Author list continued on next page)

Summary

Chromatin is essentially an array of nucleosomes, each of which consists of the DNA double-stranded fiber wrapped around a histone octamer. This organization supports cellular processes such as DNA replication, DNA transcription, and DNA repair in all eukaryotes. Human histone H4 is encoded by fourteen canonical histone H4 genes, all differing at the nucleotide level but encoding an invariant protein. Here, we present a cohort of 29 subjects with *de novo* missense variants in six H4 genes (*H4C3*, *H4C4*, *H4C5*, *H4C6*, *H4C9*, and *H4C11*) identified by whole-exome sequencing and matchmaking. All individuals present with neurodevelopmental features of intellectual disability and motor and/or gross developmental delay, while non-neurological features are more variable. Ten amino acids are affected, six recurrently, and are all located within the H4 core or C-terminal tail. These variants cluster to specific regions of the core H4 globular domain, where protein-protein interactions occur with either other histone subunits or histone chaperones. Functional consequences of the identified variants were evaluated in zebrafish embryos, which displayed abnormal general development, defective head organs, and reduced body axis length, providing compelling evidence for the causality of the reported disorder(s). While multiple developmental syndromes have been linked to chromatin-associated factors, missense-bearing histone variants (e.g., H3 oncohistones) are only recently emerging as a major cause of pathogenicity. Our findings establish a broader involvement of H4 variants in developmental syndromes.

Histones are among the most slowly evolving genes in eukaryotes.^{1,2} Histone H4 acts as a functional unit by forming a dimer with H3, but unlike H3, there are no variant isoforms linked to specific cellular processes. We previously reported four individuals with a primordial dwarfism phenotype with *de novo* missense variants affecting Lys91 in *H4C3* (*HIST1H4C*; MIM: 602827) and *H4C11* (*HIST1H4I*; MIM: 602826), a critical residue near the C terminus of the protein prone to post-translational modifications (PTMs) such as acetylation³ or, more important here, ubiquitination.^{4–6} So-

matic variation in H4 is potentially relevant in a cancer setting,^{7,8} although described variation impacts multiple residues in contrast to the highly recurrent pathogenic variants observed for the established oncohistone, H3.⁸ This could be because while the functional importance of PTMs on N-tails of H3 is linked directly to the chromatin effectors targeting these sites,^{9–11} variants affecting the histone core (H4 in this case) have more direct and global consequences on chromatin organization, as they impact nucleosome structure and dynamics.¹²

¹Hubrecht Institute-KNAW and University Medical Center Utrecht, Uppsalalaan 8, 3584 Utrecht, the Netherlands; ²Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, 3584 Utrecht, the Netherlands; ³Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand; ⁴Bristol Regional Genetics Service, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS2 8EG, UK; ⁵Amsterdam UMC, Afdeling Klinische genetica, 1081 Amsterdam, the Netherlands; ⁶Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; ⁷Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA; ⁸Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115, USA; ⁹Clinical Genetics, Hunter Genetics Unit, Waratah, NSW 2298, Australia; ¹⁰Institute of Medical Genetics, 81675 Munchen, Germany; ¹¹Institute of Neurogenetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany; ¹²Division of Child Neurology and Inherited Metabolic Diseases, Department of Pediatrics, Heidelberg University Hospital, 69120 Heidelberg, Germany; ¹³Section of Genetics and Metabolism, Department of Pediatrics, The Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; ¹⁴University of Missouri-Kansas City School of Medicine, Kansas City, MO 64108, USA; ¹⁵Center for Genomic Medicine, Children's Mercy Research Institute, Kansas City, MO 64108, USA; ¹⁶Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas

(Affiliations continued on next page)

© 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Eduardo Calpena,⁴⁰ Andrew O.M. Wilkie,⁴⁰ Maya Chopra,⁴¹ Valerie Cormier-Daire,⁴² Boris Keren,⁴³ Alexandra Afenjar,⁴⁴ Marcello Niceta,⁴⁵ Alessandra Terracciano,⁴⁶ Nicola Specchio,⁴⁷ Marco Tartaglia,⁴⁵ Marlene Rio,⁴⁸ Giulia Barcia,⁴⁸ Sophie Rondeau,⁴⁸ Cindy Colson,⁴⁹ Jeroen Bakkers,^{1,50} Peter D. Mace,³ Louise S. Bicknell,^{3,*} and Gijb van Haaften^{2,*}

We have identified an additional cohort of 29 individuals with *de novo* missense variants in six different histone H4 genes: *H4C3* (*HIST1H4C*), *H4C4* (*HIST1H4D*; MIM: 602823), *H4C5* (*HIST1H4E*; MIM: 602830), *H4C6* (*HIST1H4F*; MIM: 602824), *H4C9* (*HIST1H4I*; MIM: 602833), and *H4C11* (*HIST1H4J*) (Figure 1A, Table 1). The cohort was collected with trio-based whole-exome sequencing in combination with data sharing via GeneMatcher¹³ and DECIPHER.¹⁴ This study received ethical approval from the New Zealand Health and Disability Ethics Committee (16/STH/3) and London–Riverside REC (09/H0706/20). All families provided consent to be involved in this project and separate consent was obtained for the use of photos.

There are fourteen canonical histone H4 genes in the human genome, clustering in three genomic loci. At a nucleotide level, all genes are different, but together they encode an identical protein. Transcription of these genes is independently regulated, and differing expression levels are observed during brain development^{15,16} and in human tissues.⁴ The genes harboring variants identified in our cohort are among the more highly expressed, however, as H4 transcripts are not polyadenylated and therefore missed in most RNA sequencing (RNA-seq) protocols, limited expression data are available.

All variants observed were absent from control databases (1KG, gnomAD v2.1.1).¹⁷ Furthermore, there were no missense variants affecting Lys91 in any of the 14 canonical histone H4 genes in gnomAD, and only extremely rarely were substitutions observed for the other positions

in different H4 genes. The absence of any substitutions at Lys91 could reflect a stronger requirement for fidelity at this position, especially given the post-translation modifications of Lys91.¹⁸

The genetic findings of the cohort are striking, especially given that histones are some of the slowest evolving eukaryotic proteins and human H4 is 92% conserved with the yeast ortholog.^{1,2} In the human population, the histone H4 genes are tolerant to both loss-of-function and missense variation (gnomAD). We identify nine sites across the 103 amino acid protein with a variant, six of which were found recurrently (Pro32, Arg40, Arg45, His75, Lys91, and Tyr98), including two where the same site (Pro32 and Arg40) is altered in multiple different H4 genes. All sites are conserved through to *Saccharomyces cerevisiae*. The altered residues cluster in two main regions of histone H4 (Figure 1B); one cluster centers on the first α -helix of H4 (Figure 1B; purple spheres), a region important for DNA contacts and protein interactions with H3 and histone chaperones.¹⁸ Arg45 is positioned in the loop following the first α -helix and forms one of the sprockets of the nucleosome that contacts the minor groove of DNA. Substitutions at Arg45 in *S. cerevisiae* have proven to be deleterious to growth and fitness with altered chromatin remodeling.^{7,19,20} The second cluster is within the core of the nucleosome (Figure 1B, orange spheres), where important structural contacts exist between the H3-H4 dimer and with histone chaperones.¹⁸ Suggestive evidence for these other variants also originates from *S. cerevisiae*, where a Gly94 mutant (a key residue for H4 C-terminal flexibility)

City, MO 64108, USA; ¹⁷Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA; ¹⁸Division of Medical Genetics, Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA; ¹⁹Department of Clinical Genetics, Leiden University Medical Center, 2333 Leiden, the Netherlands; ²⁰Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand; ²¹Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK; ²²Department of Human Genetics, Radboud University Medical Centre, 6500 HB Nijmegen, the Netherlands; ²³Department of Genetics, University Medical Centre Utrecht, 3584 CX Utrecht, the Netherlands; ²⁴Genetics Laboratory, UDIAT-Centre Diagnòstic, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain; ²⁵Paediatric Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain; ²⁶Kaplan Medical Center, Clalit Health Services, Rehovot 76100, Israel; ²⁷Praxis für Humangenetik Tübingen, 72076 Tuebingen, Germany; ²⁸Service of Genetic Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; ²⁹Department of Genetic Medicine, University Hospitals of Geneva and University of Geneva Medical Faculty, Geneva 1211, Switzerland; ³⁰UMR1231 GAD, Inserm – Université Bourgogne-Franche Comté, 21078 Dijon, France; ³¹Centre de Référence Déficiences Intellectuelles de Causes Rares, Dijon Bourgogne University Hospital, 21079 Dijon, France; ³²Centre de Référence Maladies Rares “Anomalies du développement et syndromes malformatifs,” Centre de Génétique, FHU-TRANSLAD, Dijon Bourgogne University Hospital, 21079 Dijon, France; ³³Department of Pediatrics, Naval Medical Center San Diego, San Diego, CA 92134, USA; ³⁴Ambry Genetics, CA 92656, USA; ³⁵Univ. Lille, RADEME EA7364, CHU Lille, Institut de Génétique Médicale, 59000 Lille, France; ³⁶Department of Clinical Genetics, CHU Lille, 59000 Lille, France; ³⁷Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK; ³⁸Service de Génétique Médicale, CHU d'Angers, 49933 Angers, France; ³⁹Center for Human Genetics, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium; ⁴⁰MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; ⁴¹Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Boston, MA 02115, USA; ⁴²Université de Paris, Department of Clinical Genetics and Reference Centre for Constitutional Bone Diseases, INSERM U1163, Imagine Institute, Necker-Enfants Malades Hospital, AP-HP, 75015 Paris, France; ⁴³Genetic Department, APHP, Sorbonne Université, Pitié-Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013 Paris, France; ⁴⁴CRMR Malformations et Maladies Congénitales du Cervelet et Déficiences Intellectuelles de Causes Rares, Département de Génétique, Sorbonne Université, AP-HP, Hôpital Trousseau, 75012 Paris, France; ⁴⁵Area di Ricerca Genetica e Malattie Rare, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy; ⁴⁶Area di Ricerca Medicina Multimodale di Laboratorio, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy; ⁴⁷Area di Ricerca Scienze Neurologiche e Medicina Riabilitativa, Ospedale Pediatrico Bambino Gesù, IRCCS, 00163 Rome, Italy; ⁴⁸Department of Genetics, Necker Enfants Malades Hospital, Paris Descartes-Sorbonne Paris Cité University, 75015 Paris, France; ⁴⁹CHU Lille, Clinique de Génétique, 59000 Lille, France; ⁵⁰Department of Pediatric Cardiology, Division of Pediatrics, University Medical Center Utrecht, 3584 Utrecht, the Netherlands

*Correspondence: louise.bicknell@otago.ac.nz (L.S.B.), g.vanhaaften@umcutrecht.nl (G.v.H.)

<https://doi.org/10.1016/j.ajhg.2022.02.003>

Number of individuals	Gene	Chromosomal position (hg38)	cDNA	Protein	H4 ^a numbering	CADD PHRED	REVEL score
1	<i>H4C3</i>	6: 26,104,044	c.97C>G	p.Pro33Ala	Pro32Ala	23.1	0.526
2	<i>H4C3</i>	6: 26,104,045	c.98C>T	p.Pro33Leu	Pro32Leu	25.7	0.438
3	<i>H4C3</i>	6: 26,104,221	c.274A>C	p.Lys92Gln	Lys91Gln	26.6	0.706
1	<i>H4C4</i>	6: 26,188,955	c.122G>A	p.Arg41His	Arg40His	23.9	0.459
1	<i>H4C5</i>	6: 26,204,739	c.95A>C	p.Lys32Thr	Lys31Thr	26.6	0.523
1	<i>H4C5</i>	6: 26,204,742	c.98C>G	p.Pro33Arg	Pro32Arg	25.3	0.541
1	<i>H4C5</i>	6: 26,204,750	c.106C>T	p.Arg36Trp	Arg35Trp	26.6	0.494
1	<i>H4C5</i>	6: 26,204,757	c.113T>C	p.Leu38Pro	Leu37Pro	27.5	0.659
4	<i>H4C5</i>	6: 26,204,765	c.121C>T	p.Arg41Cys	Arg40Cys	26.6	0.446
7	<i>H4C5</i>	6: 26,204,780	c.136C>T	p.Arg46Cys	Arg45Cys	26.3	0.589
2	<i>H4C5</i>	6: 26,204,939	c.295T>C	p.Tyr99His	Tyr98His	26.9	0.317
1	<i>H4C6</i>	6: 26,240,708	c.283G>A	p.Gly95Arg	Gly94Arg	24.5	0.677
1	<i>H4C9</i>	6: 27,139,430	c.122G>T	p.Arg41Leu	Arg40Leu	26.7	0.628
2	<i>H4C9</i>	6: 27,139,535	c.227A>G	p.His76Arg	His75Arg	25.3	0.754
1	<i>H4C11</i>	6: 27,824,245	c.121C>T	p.Arg41Cys	Arg40Cys	25.8	0.541

RefSeq IDs: GenBank: NM_003542.4 (*H4C3*), GenBank: NM_003539.4 (*H4C4*), GenBank: NM_003545.3 (*H4C5*), GenBank: NM_003540.4 (*H4C6*), GenBank: NM_003495.2 (*H4C9*), GenBank: NM_021968.4 (*H4C11*).

^aNote on nomenclature: to refer to the residues belonging to this study, HGVS Variant nomenclature would include Methionine-1 (Met1) at the translation initiating site, e.g., *H4C3* Pro33Ala (c.97C>G [p.Pro33Ala]). However, as the research field of epigenetics and oncohistones typically drops this first post-translationally removed methionine, we have also done so. Therefore, the above-mentioned example (included in this study) is referred to as *H4C3* Pro32Ala.

confers reduced viability,²¹ whereas a His75 mutant disrupts DNA damage repair processes.²² Other studied variants in similar regions (either somatic “oncohistone” variants in H4,^{7,8} or recently described germline variants in H3²³) are predicted to perturb either nucleosome stability or interaction with histone chaperones, suggesting the H4 variants described in our cohort most likely cause similar effects. These complementary observations, alongside the significant recurrence of specific variants, provide strong evidence for pathogenicity.

All individuals displayed intellectual disability (ID) and the majority demonstrated global and/or gross motor developmental delay (Table 2, Table S1). Other neurodevelopmental features such as hypotonia (34%), seizures (17%), or autism (17%) were present in some individuals but less common. Brain MRI was generally normal except for two individuals with delayed myelination. Microcephaly was commonly observed (Figure 2A); an occipito-frontal circumference Z score smaller than −2 SD was evident in 16% of individuals at birth and became progressively more severe with age (76% at the most recent exam). Short stature (defined as Z score for height smaller than −2 SD) and failure to thrive were common features (38%), however without significant change over time (Figure 2A). Clustering of anthropometric data by H4 gene or protein region revealed no obvious genotype-phenotype patterns (Figure 2A). The age range of the cohort is between 10 months and 52 years. Interestingly, the oldest individual shows signs of premature aging

with greyed, thinning hair and wrinkly skin, looking at least two decades beyond his biological age, which did not occur in his parents. Premature aging has also been observed in Rahman syndrome (MIM: 617537), caused by pathogenic variants in *H1-4* (*HIST1H1E*; MIM: 142220).²⁴ This phenotype appears to be milder in our H4 cohort, however the majority of the individuals are still quite young. One individual died from leukemia stemming from myelodysplasia (P28), but no other individuals were reported to have bone marrow abnormalities.

Non-neurological features were variable across the cohort. Facial features comprised a wide spectrum (Figure 2B). While some individuals were relatively nondysmorphic, others had a common presentation affecting the facial midline, with hypertelorism (17%), a high nasal bridge (or conversely very low nasal bridge) with a broad nasal base (38%) and narrow nares, wide mouth with a gap between central incisors or other tooth anomalies (21%) (Figure 2C), and moderately pointy chin. Visual impairment such as strabismus, astigmatism, or myopia were reasonably common (61% individuals), and 24% individuals demonstrated hearing impairment. Skeletal development was normal for most individuals, however recurring features such as vertebral or digit abnormalities were present in several individuals (Figure 2D), and particularly severe in individual P28. Variability in clinical features and growth was noted even among the seven individuals harboring the same *de novo* variant in *H4C5* encoding Arg45Cys (Figure 2B, Figure S1).

Table 2. Clinical features of individuals in the H4 cohort

Clinical feature	Proportion (percentage)
Neurodevelopment	
Intellectual disability	29/29 (100%)
Developmental delay	29/29 (100%)
Hypotonia	10/29 (34%)
Seizures	5/29 (17%)
Autism	5/29 (17%)
Ataxia	4/29 (14%)
Growth	
Microcephaly—prenatal onset	2/19 (11%)
Microcephaly—postnatal	20/29 (69%)
Short stature	11/29 (38%)
Failure to thrive	11/29 (38%)
Skeletal features	
Craniosynostosis	2/29 (7%)
Digit anomalies	4/29 (14%)
Vertebral anomalies	4/27 (15%)
Facial features	
Hypertelorism	5/29 (17%)
Upslanting palpebral fissures	3/29 (10%)
Broad nasal tip	11/29 (38%)
Thin upper lip/vermillion	4/29 (14%)
Teeth anomalies	6/29 (21%)
Other features	
Recurrent infections	4/29 (14%)
Visual impairment	17/28 (61%)
Hearing impairment	7/29 (24%)
Age range	10 months – 52 years (median 10 years 11 months)

To validate the pathogenic effect of these variants, we expressed wild-type human histone H4 and the histone H4 variants pertaining to this study in zebrafish by means of mRNA microinjection (Figure 3). The complete conservation of the zebrafish and human histone H4 proteins at the amino acid sequence level and the early, mRNA-mediated ectopic overexpression make this an optimal set-up for assaying the variants' effect on early development. Early embryonic effects were evaluated at 28 hours post fertilization (hpf) as fundamental developmental processes such as gastrulation and primary organogenesis are completed by this time point. All variants tested displayed significant visible developmental effects compared to microinjection of the corresponding wild-type H4 gene, except the Pro32Ala and Arg40Cys variants. Specifically, classification was based on cephalic development, ante-

rior-posterior axis establishment, and tissue necrosis during early embryonic development, as these parameters captured the major defects and the cellular toxicity (Figures 3A–3C) observed across all variants analyzed. Phenotypic observation revealed that variants affecting Lys91 and His75 caused the strongest effects. Interestingly, these two variants both cluster at the core of the nucleosome, and His75 plays a role in DNA damage repair,²² a process previously suggested to be involved in the syndromic features of Lys91 individuals.⁴ His75 is at the interface between two histone molecules within the octamer (in this case, H4 and H2B) and it is located in the *lrs* (loss-of-ribosomal DNA silencing) domain of H4,²² a nucleosomal surface structure reported to have gene-specific silencing function in yeast.¹⁹ Additionally, we observed a dosage-dependent effect for Arg40His and Arg45Cys (Figures 3D and 3E), which has been noted for other sprocket arginine substitutions and may relate to possible roles in higher-order organization of chromatin.²⁵ Interestingly, such sprocket function has been reported for both the *sin* (switch-independent) and *lrs* H4 domains containing Arg45 and His75, respectively.²⁶ These regions have an almost identical three-dimensional structure²⁶ and play a role in gene regulation (repression), the perturbation of which most likely results in pathogenicity and was detected in our functional assay. The variability in frequency of phenotype occurrence across variants may reflect the importance of the affected residues in cellular processes crucial to active cell proliferation, as the early zebrafish embryo is a system in which cells have a relatively short cell-cycle time. The milder effect observed in our functional assay for variants affecting Pro32 and Arg40 may point to a moderate requirement, however the strong recurrence of variants affecting these residues in our cohort provides alternative evidence to support their pathogenicity. Altogether, these results provide a first picture of the variety of phenotypes caused by the assayed variants, supporting our genetic data. However, as their interpretation is limited by their transience and the inherent variability of our current mRNA assay, further testing in a stable model is required to obtain more insight in the molecular mechanisms linking genetic variants and phenotype.

Through genetic and developmental findings, we have identified pathogenic substitutions in six genes encoding histone H4 in a large cohort of individuals with a neurodevelopmental syndrome. Despite well-established cellular requirements for post-translational modification of the N-terminal tail of H4,^{27–29} it is notable that no *de novo* variants were identified in this region.

Recently, a large cohort of individuals with a neurodegenerative and developmental disorder were reported harboring *de novo* missense variants in the histone H3 replication-independent genes *H3F3A* (MIM: 601128) and *H3F3B* (MIM: 601058).²³ While there are phenotypic commonalities between the H3.3 cohort and individuals presented here, the presentations are distinct. The H3F3A/H3F3B cohort appears to have a more expansive neurological dysfunction with




Figure 2. Clinical characteristics of individuals with histone H4 gene variants

(A) Individuals with variants in histone H4 genes demonstrate a reduction in height, weight, and brain growth (OFC, occipitofrontal circumference); the latter significantly progresses as the individuals age. There are no detectable genotype-phenotype patterns separating by the specific histone H4 gene or variant cluster. **** $p < 0.0001$.

(B) Facial dysmorphism affecting midline structures is noticeable among the cohort, but highly variable, with no obvious genotype-phenotype correlation.

(C) Individuals can present with abnormalities in the appearance and position of teeth (for example, P5, P25). A recurring feature present in several individuals is a noticeable gap between the upper central incisors.

(D) Individuals with variants in histone H4 genes also show a spectrum of toe anomalies, ranging from no anomalies present (for example, P21) through to severe 2–3 toe (P1, P28) or 3–4 toe (P25) syndactyly, which can be bilateral. Toes can also be short (P19, P28).

anomalies noted on imaging, accompanied by septal or genital abnormalities and craniosynostosis. In contrast, our H4 cohort has ID/DD and microcephaly as presenting features, but only more rarely are there other neurodevelopmental abnormalities. The pathogenic variants identified in *H3F3A* and *H3F3B* are located throughout the protein, with a smaller number of recurrently occurring variants. In comparison, for histone H4, the high level of recurrent variants

observed is significant, along with the clear clustering of the variants in two regions of the H4 protein.

The redundancy of the H4 genes in the human genome is remarkable. Loss-of-function variants in H4 genes are present in the healthy population¹⁷ and are even present in homozygous form,³⁰ supporting our hypothesis that the variants identified here act through a dominant effect. This disease mechanism, combined with the paralogous




Figure 3. H4 variants induce developmental defects in zebrafish embryos

(A) Phenotypic characterization in 28 hpf embryos. Representative images of observed phenotypes in zebrafish embryos 28 hpf microinjected with mRNA encoding either wild-type or identified variants at the one-cell stage. The different classes are defined on general development and necrosis. Arrowhead, cephalic necrosis; arrow, curved tail. (B and C) High magnification examples of cephalic necrosis (B) and curved tail (C) phenotypes.

(D and E) Quantification of the phenotypic classification as described in (A). Variants reported in (D) were microinjected with 50 pg/embryo, and additional testing with 100 pg/embryo is reported in (E). Data marked with a hash symbol was previously published in Tessadori et al.⁴ Fisher's exact test: ns, not significant; $p > 0.05$; * $p < 0.05$; **** $p < 0.0001$. Scale bars: 100 μ m (A); 50 μ m (B and C).

landscape of H4 genes, presents opportunities for future treatment strategies through targeted knockdown of specific H4 gene products.

Data and code availability

Full genetic data are not available due to privacy regulations.

Supplemental information

Supplemental information can be found online at <https://doi.org/10.1016/j.ajhg.2022.02.003>.

Acknowledgments

The authors thank all individuals and their families who were involved in this study; Marine Tessarech for molecular diagnostic assistance; Anisha Chopra for experimental work; and Jacques Giltay, Meriel McEntagart, and Cynthia Morton for advice. F.T. is supported by NWO grant NWO/OCENW. GROOT.2019.029. A.O.M.W. was supported by the NIHR Oxford Biomedical Research Centre, K.K. and L.S.B. were supported by the Marsden Fund, and L.S.B. was supported by a Rutherford Discovery Fellowship, both administered by the Royal Society of New Zealand. A.O.D.L. is supported by a Manton Endowed Scholar award. Project support was provided

by Fondazione Bambino Gesù (Vite Coraggiose), Italian Ministry of Health (5x1000, CCR-2017-23669081 and RCR-2020-23670068_001), Italian Ministry of Research (FOE 2019), and the Cliff Broad Family Trust, administered by the Neurological Foundation of New Zealand. The opinions expressed here are those of the authors and do not reflect those of the Navy, the Department of Defense, or the United States government. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant HICF-1009-003), a parallel funding partnership between the Wellcome Trust with the Department of Health and the Wellcome Trust Sanger Institute (grant WT098051). The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health. The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12, granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research through the Comprehensive Clinical Research Network.

Declaration of interests

The authors declare no competing interests.

Received: November 24, 2021

Accepted: February 3, 2022

Published: February 23, 2022

Web resources

Online Mendelian Inheritance in Man, <https://omim.org/>

References

1. Kamakaka, R.T., and Biggins, S. (2005). Histone variants: deviants? *Genes Dev.* 19, 295–310. <https://doi.org/10.1101/gad.1272805>.
2. Pusarla, R.H., and Bhargava, P. (2005). Histones in functional diversification. Core histone variants. *FEBS J.* 272, 5149–5168. <https://doi.org/10.1111/j.1742-4658.2005.04930.x>.
3. Ye, J., Ai, X., Eugeni, E.E., Zhang, L., Carpenter, L.R., Jelinek, M.A., Freitas, M.A., and Parthun, M.R. (2005). Histone H4 lysine 91 acetylation a core domain modification associated with chromatin assembly. *Mol. Cell* 18, 123–130. <https://doi.org/10.1016/j.molcel.2005.02.031>.
4. Tessadori, F., Giltay, J.C., Hurst, J.A., Massink, M.P., Duran, K., Vos, H.R., van Es, R.M., Scott, R.H., van Gassen, K.L.I., Bakkers, J., van Haaften, G.; and Deciphering Developmental Disorders Study (2017). Germline mutations affecting the histone H4 core cause a developmental syndrome by altering DNA damage response and cell cycle control. *Nat. Genet.* 49, 1642–1646. <https://doi.org/10.1038/ng.3956>.
5. Tessadori, F., Rehman, A.U., Giltay, J.C., Xia, F., Streff, H., Duran, K., Bakkers, J., Lalani, S.R., and van Haaften, G. (2020). A de novo variant in the human HIST1H4J gene causes a syndrome analogous to the HIST1H4C-associated neurodevelopmental disorder. *Eur. J. Hum. Genet.* 28, 674–678. <https://doi.org/10.1038/s41431-019-0552-9>.
6. Yan, Q., Dutt, S., Xu, R., Graves, K., Juszczynski, P., Manis, J.P., and Shipp, M.A. (2009). BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. *Mol. Cell* 36, 110–120. <https://doi.org/10.1016/j.molcel.2009.08.019>.
7. Bagert, J.D., Mitchener, M.M., Patriotis, A.L., Dul, B.E., Wojcik, F., Nacev, B.A., Feng, L., Allis, C.D., and Muir, T.W. (2021). Oncohistone mutations enhance chromatin remodeling and alter cell fates. *Nat. Chem. Biol.* 17, 403–411. <https://doi.org/10.1038/s41589-021-00738-1>.
8. Nacev, B.A., Feng, L., Bagert, J.D., Lemiesz, A.E., Gao, J., Soshnev, A.A., Kundra, R., Schultz, N., Muir, T.W., and Allis, C.D. (2019). The expanding landscape of ‘oncohistone’ mutations in human cancers. *Nature* 567, 473–478. <https://doi.org/10.1038/s41586-019-1038-1>.
9. Lewis, P.W., Müller, M.M., Koletsky, M.S., Cordero, F., Lin, S., Banaszynski, L.A., Garcia, B.A., Muir, T.W., Becher, O.J., and Allis, C.D. (2013). Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. *Science* 340, 857–861. <https://doi.org/10.1126/science.1232245>.
10. Lu, C., Jain, S.U., Hoelper, D., Bechet, D., Molden, R.C., Ran, L., Murphy, D., Venneti, S., Hameed, M., Pawel, B.R., et al. (2016). Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. *Science* 352, 844–849. <https://doi.org/10.1126/science.aac7272>.
11. Papillon-Cavanagh, S., Lu, C., Gayden, T., Mikael, L.G., Bechet, D., Karamboulas, C., Ailles, L., Karamchandani, J., Marchione, D.M., Garcia, B.A., et al. (2017). Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. *Nat. Genet.* 49, 180–185. <https://doi.org/10.1038/ng.3757>.
12. Tropberger, P., and Schneider, R. (2013). Scratching the (lateral) surface of chromatin regulation by histone modifications. *Nat. Struct. Mol. Biol.* 20, 657–661. <https://doi.org/10.1038/nsmb.2581>.
13. Sobreira, N., Schiettecatte, F., Valle, D., and Hamosh, A. (2015). GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum. Mutat.* 36, 928–930. <https://doi.org/10.1002/humu.22844>.
14. Firth, H.V., Richards, S.M., Bevan, A.P., Clayton, S., Corpas, M., Rajan, D., Van Vooren, S., Moreau, Y., Pettett, R.M., and Carter, N.P. (2009). DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. *Am. J. Hum. Genet.* 84, 524–533. <https://doi.org/10.1016/j.ajhg.2009.03.010>.
15. Miller, J.A., Ding, S.L., Sunkin, S.M., Smith, K.A., Ng, L., Szafer, A., Ebbert, A., Riley, Z.L., Royall, J.J., Aiona, K., et al. (2014). Transcriptional landscape of the prenatal human brain. *Nature* 508, 199–206. <https://doi.org/10.1038/nature13185>.
16. Pollen, A.A., Nowakowski, T.J., Chen, J., Retallack, H., Sandoval-Espinosa, C., Nicholas, C.R., Shuga, J., Liu, S.J., Oldham, M.C., Diaz, A., et al. (2015). Molecular identity of human outer radial glia during cortical development. *Cell* 163, 55–67. <https://doi.org/10.1016/j.cell.2015.09.004>.
17. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alfoldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581, 434–443. <https://doi.org/10.1038/s41586-020-2308-7>.
18. Tessarz, P., and Kouzarides, T. (2014). Histone core modifications regulating nucleosome structure and dynamics. *Nat. Rev. Mol. Cell Biol.* 15, 703–708. <https://doi.org/10.1038/nrm3890>.
19. Kruger, W., Peterson, C.L., Sil, A., Coburn, C., Arents, G., Moudrianakis, E.N., and Herskowitz, I. (1995). Amino acid substitutions in the structured domains of histones H3 and H4 partially relieve the requirement of the yeast SWI/SNF complex for transcription. *Genes Dev.* 9, 2770–2779. <https://doi.org/10.1101/gad.9.22.2770>.
20. Luger, K., Mäder, A.W., Richmond, R.K., Sargent, D.F., and Richmond, T.J. (1997). Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* 389, 251–260. <https://doi.org/10.1038/38444>.
21. Chavez, M.S., Scorgie, J.K., Dennehey, B.K., Noone, S., Tyler, J.K., and Churchill, M.E. (2012). The conformational flexibility of the C-terminus of histone H4 promotes histone octamer and nucleosome stability and yeast viability. *Epigenetics Chromatin* 5, 5. <https://doi.org/10.1186/1756-8935-5-5>.
22. Selvam, K., Rahman, S.A., and Li, S. (2019). Histone H4 H75E mutation attenuates global genomic and Rad26-independent transcription-coupled nucleotide excision repair. *Nucleic Acids Res.* 47, 7392–7401. <https://doi.org/10.1093/nar/gkz453>.
23. Bryant, L., Li, D., Cox, S.G., Marchione, D., Joiner, E.F., Wilson, K., Janssen, K., Lee, P., March, M.E., Nair, D., et al. (2020). Histone H3.3 beyond cancer: Germline mutations in *Histone 3 Family 3A and 3B* cause a previously unidentified neurodegenerative disorder in 46 patients. *Sci. Adv.* 6, eabc9207. <https://doi.org/10.1126/sciadv.abc9207>.
24. Flex, E., Martinelli, S., Van Dijck, A., Ciolfi, A., Cecchetti, S., Coluzzi, E., Pannone, L., Andreoli, C., Radio, F.C., Pizzi, S., et al. (2019). Aberrant Function of the C-Terminal Tail of

- HIST1H1E Accelerates Cellular Senescence and Causes Premature Aging. *Am. J. Hum. Genet.* 105, 493–508. <https://doi.org/10.1016/j.ajhg.2019.07.007>.
25. Hodges, A.J., Gallegos, I.J., Laughery, M.F., Meas, R., Tran, L., and Wyrick, J.J. (2015). Histone Sprocket Arginine Residues Are Important for Gene Expression, DNA Repair, and Cell Viability in *Saccharomyces cerevisiae*. *Genetics* 200, 795–806. <https://doi.org/10.1534/genetics.115.175885>.
 26. Park, J.H., Cosgrove, M.S., Youngman, E., Wolberger, C., and Boeke, J.D. (2002). A core nucleosome surface crucial for transcriptional silencing. *Nat. Genet.* 32, 273–279. <https://doi.org/10.1038/ng982>.
 27. Sanders, S.L., Portoso, M., Mata, J., Bähler, J., Allshire, R.C., and Kouzarides, T. (2004). Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. *Cell* 119, 603–614. <https://doi.org/10.1016/j.cell.2004.11.009>.
 28. Shogren-Knaak, M., Ishii, H., Sun, J.M., Pazin, M.J., Davie, J.R., and Peterson, C.L. (2006). Histone H4-K16 acetylation controls chromatin structure and protein interactions. *Science* 311, 844–847. <https://doi.org/10.1126/science.1124000>.
 29. Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter, G., Reinberg, D., and Jenuwein, T. (2004). A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. *Genes Dev.* 18, 1251–1262. <https://doi.org/10.1101/gad.300704>.
 30. DeBoever, C., Tanigawa, Y., Lindholm, M.E., McInnes, G., Lavertu, A., Ingelsson, E., Chang, C., Ashley, E.A., Bustamante, C.D., Daly, M.J., and Rivas, M.A. (2018). Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. *Nat. Commun.* 9, 1612. <https://doi.org/10.1038/s41467-018-03910-9>.